Drug intelligence / Profile preview

BNT162b1

Development stage: Phase 2
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

BNT162b1 is an experimental nucleoside-modified messenger RNA (modRNA) vaccine candidate developed by BioNTech in collaboration with Pfizer and Fosun Pharma for the prevention of COVID-19. It encodes the trimerized receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, formulated in lipid nanoparticles (LNPs). Unlike its sibling candidate BNT162b2 (tozinameran), which encodes the full-length spike protein, BNT162b1 focuses specifically on the RBD to elicit neutralizing antibodies. While it demonstrated robust immunogenicity in early-phase clinical trials, the development program ultimately prioritized BNT162b2 for global pivotal trials and commercialization due to a more favorable safety profile and broader immune response.

Other names: SARS-CoV-2 mRNA vaccine (BNT162b1)

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on BNT162b1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT162b1.

Explore the full profile